The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Open accessAbstract
BACKGROUND: Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7. METHODS: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activity Index (CDAI) score of less than 150, with maintenance of remission for at least 2 weeks, and the safety of mongersen treatment. A secondary outcome was clinical response (defined as a reduction of 100 points or more in the CDAI score) at day 28. RESULTS: The proportions of patients who reached the primary end point were 55% and 65% for the 40-mg and 160-mg mongersen groups, respectively, as compared with 10% for the placebo group (P<0.001). There was no significant difference in the percentage of participants reaching clinical remission between the 10-mg group (12%) and the placebo group. The rate of clinical response was significantly greater among patients receiving 10 mg (37%), 40 mg (58%), or 160 mg (72%) of mongersen than among those receiving placebo (17%) (P=0.04, P<0.001, and P<0.001, respectively). Most adverse events were related to complications and symptoms of Crohn's disease. CONCLUSIONS: We found that study participants with Crohn's disease who received mongersen had significantly higher rates of remission and clinical response than those who received placebo. (Funded by Giuliani; EudraCT number, 2011-002640-27.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Chang, P. V., Hao, L., Offermanns, S., & Medzhitov, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322269111 · Cited by 2,175
Van Assche, G., Dignass, A., Panes, J., Beaugerie, L., Karagiannis, J., Allez, M., Ochsenkühn, T., Orchard, T., Rogler, G., Louis, E., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.003 · Cited by 1,453
Louis, E., Collard, A., Oger, A. F., Degroote, E., El Yafi, F. A. N., & Belaiche, J. (2001) · Gut · doi:10.1136/gut.49.6.777 · Cited by 1,005
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 962
European consensus on the histopathology of inflammatory bowel disease
Magro, F., Langner, C., Driessen, A., Ensari, A., Geboes, K., Mantzaris, G. J., Villanacci, V., Becheanu, G., Nunes, P. B., Cathomas, G., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.06.001 · Cited by 731
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease
Monteleone, G., Kumberova, A., Croft, N. M., McKenzie, C., Steer, H. W., & MacDonald, T. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12821 · Cited by 600
Self-citation
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Gut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Self-citationCurrent and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Self-citationTreatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Long noncoding RNAs in cancer metastasis
Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y., & Maher, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00353-1 · Cited by 648
Resolution of Inflammation: What Controls Its Onset?
Sugimoto, M. A., Sousa, L. P., Pinho, V., Perretti, M., & Teixeira, M. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00160 · Cited by 638
The Gut Microbiota in Inflammatory Bowel Disease
Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.733992 · Cited by 591
Regulation of TGF-β Family Signaling by Inhibitory Smads
Miyazawa, K., & Miyazono, K. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022095 · Cited by 439
“Remarkably, an oral SMAD7 antisense oligonucleotide (Mongersen) was effective in the treatment of patients with active Crohn’s disease in a phase II study (Monteleone et al. 2015), supporting a role of Smad7 in the pathogenesis of the disease.”
BackgroundPharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Biomarkers of Inflammation in Inflammatory Bowel Disease
Sands, B. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.003 · Cited by 405
Strategies for targeting cytokines in inflammatory bowel disease
Neurath, M. F. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01008-6 · Cited by 398
Self-citationBaker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Moroz, E., Matoori, S., & Leroux, J.-C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.010 · Cited by 336
Antisense technology: A review
Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 326
Ihara, S., Hirata, Y., & Koike, K. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1350-1 · Cited by 302
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Kim, D. H., & Cheon, J. H. (2017) · Immune Network · doi:10.4110/in.2017.17.1.25 · Cited by 295
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Th17 plasticity and its relevance to inflammatory bowel disease
Ueno, A., Jeffery, L., Kobayashi, T., Hibi, T., Ghosh, S., & Jijon, H. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.12.004 · Cited by 266
Ki67 targeted strategies for cancer therapy
Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1774-3 · Cited by 254
Big data in IBD: a look into the future
Olivera, P., Danese, S., Jay, N., Natoli, G., & Peyrin-Biroulet, L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0102-5 · Cited by 151
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
The selection landscape and genetic legacy of ancient Eurasians
Irving-Pease, E. K., Refoyo-Martínez, A., Barrie, W., Ingason, A., Pearson, A., Fischer, A., Sjögren, K.-G., Halgren, A. S., Macleod, R., Demeter, F., et al. (2024) · Nature · doi:10.1038/s41586-023-06705-1 · Cited by 126
Resolution of inflammation in inflammatory bowel disease
Rogler, G. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30031-6 · Cited by 79
Fenton, T. M., Kelly, A., Shuttleworth, E. E., Smedley, C., Atakilit, A., Powrie, F., Campbell, S., Nishimura, S. L., Sheppard, D., Levison, S., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2016.94 · Cited by 64
“Indeed, recent evidence suggests that targeting the TGFb pathway in IBD may have beneficial effects in some patients.(3) Many different cells in the gut produce TGFb, but always as a latent complex, which has to be activated to function.”
BackgroundFaber, S., Lahoti, T., Taylor, E., Lewis, L., Sapiro, J., Toledo Sales, V., Dragan, Y., & Jeffy, B. (2022) · Cells · doi:10.3390/cells11101708 · Cited by 16
Metadata
- Authors
- Monteleone, G., Neurath, M. F., Ardizzone, S., Di Sabatino, A., Fantini, M. C., Castiglione, F., Scribano, M. L., Armuzzi, A., Caprioli, F., Sturniolo, G. C., Rogai, F., Vecchi, M., Atreya, R., Bossa, F., Onali, S., Fichera, M., Corazza, G. R., Biancone, L., Savarino, V., Pica, R., Orlando, A., & Pallone, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-19
- Volume
- 372
- Issue
- 12
- Pages
- 1104-1113
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112082141
- Cited by
- 401
- References
- 31
- FWCI
- 47.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.